CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05651022
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:39.212069+00:00
Published At: 2026-01-13T00:00:00+00:00
Record Updated At: 2026-01-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumor, Adult", "HCC - Hepatocellular Carcinoma", "CRC (Colorectal Cancer)", "Pancreatic Adenocarcinoma", "NSCLC Non-small Cell Lung Cancer", "Squamous Cell Cancer of the Head and Neck", "UC (Urothelial Cancer)", "MSI-H Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-13"
protocolSection.identificationModule.nctId: "NCT05651022"
protocolSection.identificationModule.officialTitle: "A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.